Drugs / TT-00920
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05355129 | Nov 2021 → Jun 2022 | — | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05043792 Comparator | Aug → Nov 2021 | — | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04364789 Comparator | Feb 2020 → Jun 2021 | — | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT-00920 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05355129 ↗ |
| Route | Oral | “following an oral dose” NCT04364789 ↗ |